news

Takeda to supply Japan with Moderna’s COVID-19 vaccine

5
SHARES

Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.

Doctor in full PPE drawing yellow liquid into a syringe from a vial labelled 'COVID-19 Vaccine'

As part of a three-way commitment between Takeda Pharmaceutical Company Limited, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW), Takeda will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021. The distribution depends on the vaccine being licensed in Japan.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Under the terms of the agreement Takeda will be responsible for securing the necessary regulatory approvals prior to distributing the doses of mRNA-1273 and Moderna will provide the finished product and support Takeda’s development and regulatory efforts.

This new agreement follows an earlier one made by Takeda in August 2020 with Novavax, where the former announced it was establishing the capability to manufacture Novavax’s COVID‑19 vaccine candidate at its facilities in Japan. The company’s efforts to bring both COVID-19 vaccine candidates to Japan are supported by the MHLW and the Japan Agency for Medical Research and Development (AMED).

“Takeda is collaborating with the Japanese Government and vaccine developers to provide rapid and sustained access to COVID-19 vaccines in Japan,” said Dr Rajeev Venkayya, President of the Global Vaccine Business Unit at Takeda. “We have chosen to work with Novavax and Moderna, both of which have promising vaccine candidates, and will continue to support the global response to COVID-19 through R&D efforts across Takeda.”

Share via
Share via